Effect of metformin on the human T98G glioblastoma multiforme cell line
- PMID: 24940426
- PMCID: PMC3991524
- DOI: 10.3892/etm.2014.1597
Effect of metformin on the human T98G glioblastoma multiforme cell line
Abstract
Metformin is a guanidine derivative found in Galega officinalis that is commonly used to treat diabetes mellitus. The mechanism of action of metformin involves regulation of the adenosine monophosphate-activated protein kinase/mammalian target of rapamycin signaling pathway, which is implicated in the control of protein synthesis and cell proliferation. This led to the hypothesis that metformin reduces the risk of cancer and slows tumor growth. Thus, in the present study, the effectiveness of metformin as an antiglioma agent was evaluated using the human T98G glioblastoma multiforme cell line. The viability of the T98G cells was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Apoptosis was monitored by measuring caspase-3 levels, as well as by terminal deoxynucleotidyl transferase dUTP nick end labeling and staining with acridine orange and ethidium bromide. The results demonstrate that metformin reduced cell viability and caused apoptotic morphological changes in the T98G cells. Furthermore, the caspase-3 levels in the metformin-treated T98G cells were higher than those in the control cells. Metformin induced apoptosis in the T98G cell line in a concentration-dependent manner. Metformin may provide an important contribution to the treatment of glioblastoma multiforme.
Keywords: T98G; apoptosis; glioblastoma cell line; metformin.
Figures




Similar articles
-
Inhibitory effect of temozolomide on apoptosis induction of cinnamaldehyde in human glioblastoma multiforme T98G cell line.Anat Cell Biol. 2024 Mar 31;57(1):85-96. doi: 10.5115/acb.23.159. Epub 2023 Nov 22. Anat Cell Biol. 2024. PMID: 37994040 Free PMC article.
-
Metformin reduces pancreatic cancer cell proliferation and increases apoptosis through MTOR signaling pathway and its dose-effect relationship.Eur Rev Med Pharmacol Sci. 2020 May;24(10):5336-5344. doi: 10.26355/eurrev_202005_21316. Eur Rev Med Pharmacol Sci. 2020. PMID: 32495867
-
Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.Mol Med Rep. 2016 Mar;13(3):2590-6. doi: 10.3892/mmr.2016.4830. Epub 2016 Jan 29. Mol Med Rep. 2016. PMID: 26847819 Free PMC article.
-
Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells.Glia. 2005 Apr 15;50(2):160-7. doi: 10.1002/glia.20168. Glia. 2005. PMID: 15685605
-
In vitro evaluation of effects of metformin on morphine and methadone tolerance through mammalian target of rapamycin signaling pathway.J Cell Physiol. 2019 Mar;234(3):3058-3066. doi: 10.1002/jcp.27125. Epub 2018 Aug 26. J Cell Physiol. 2019. PMID: 30146703
Cited by
-
Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells.Anal Cell Pathol (Amst). 2018 Jun 26;2018:5917470. doi: 10.1155/2018/5917470. eCollection 2018. Anal Cell Pathol (Amst). 2018. PMID: 30046513 Free PMC article.
-
Metformin and its Nanoformulations in Cancer Prevention and Therapy.Curr Pharm Des. 2025;31(27):2169-2199. doi: 10.2174/0113816128367242250214052019. Curr Pharm Des. 2025. PMID: 40207763 Review.
-
Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.PLoS One. 2015 Apr 13;10(4):e0123721. doi: 10.1371/journal.pone.0123721. eCollection 2015. PLoS One. 2015. PMID: 25867026 Free PMC article.
-
A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres.J Neurooncol. 2022 Jan;156(1):139-151. doi: 10.1007/s11060-021-03903-7. Epub 2021 Nov 22. J Neurooncol. 2022. PMID: 34811601
-
Drug Repositioning in Glioblastoma: A Pathway Perspective.Front Pharmacol. 2018 Mar 16;9:218. doi: 10.3389/fphar.2018.00218. eCollection 2018. Front Pharmacol. 2018. PMID: 29615902 Free PMC article. Review.
References
-
- Campbell IW. Metformin - life begins at 50: A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 2007. (Meeting Report) Br J Diabet Vasc Dis. 2007;7:247–252.
-
- Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson’s disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord. 2012;18:753–758. - PubMed
-
- Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann NY Acad Sci. 2011;1243:54–68. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials